High-dose intensification and autologous stem-cell transplantation (ASCT) is widely used to consolidate patients with nonHodgkin's lymphoma (NHL), who have reached a stage of minimal residual disease. However, patients with persisting marrow and/or blood involvement and those who fail peripheral blood hemopoietic progenitor mobilization are excluded from ASCT. For such patients with no available graft to infuse, we developed 15 years ago, before the anti-CD20 monoclonal antibody therapeutic era, the use of the BEAM pretransplant regimen followed only by the administration of three cytokines (erythropoietin, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor). We report here on the long-term follow-up of 33 patients treated with this approach. In all, 33 NHL patients underwent the BEAM (carmustine, VP-16, cytosine-arabinoside, melphalan) followed by the administration of the three cytokines from January 1994-2000. A backup marrow, albeit infiltrated by tumor cells, had been collected earlier and stored in all. A total of 30 patients (91%) recovered normal hematopoiesis. In total, 32 patients (97%) recovered neutrophils (4500/ll) at a median of 19 days and 30 patients (91%) recovered platelets (420 000/ll) at a median of 26 days. Age, richness of backup graft and bloodhemoglobin level at intensification had an impact on the time for hematopoietic recovery (P ¼ 0.014, P ¼ 0.014, P ¼ 0.048). The median follow-up was 62 months. Five patients died from toxicity related to the procedure. Eight patients relapsed and died. A total of 20 patients (61%) are alive, 16 (49%) in complete remission. A 5-year disease-free survival was 5279%, relapse incidence 35716%, mortality due to the procedure 12712% and overall survival 61710%. The BEAM regimen is not myeloablative. The BEAM þ 3CK procedure is a feasible therapeutic option that has shown efficacy in poor risk NHL patients who were not eligible for autografting because of persisting marrow/ blood tumor contamination, or poor hemopoietic progenitor harvesting. It is unclear today whether some of these patients would have cleared their marrow/peripheral blood with the additional use of anti-CD20 treatment, thereby making the classical approach (BEAM followed by the infusion of a clean autograft) feasible.
Introduction
High-dose intensification chemotherapy (HDCT) followed by autologous stem-cell transplantation (ASCT) is widely used for the management of patients with non-Hodgkin's lymphoma (NHL). Its benefit has been clearly established in high-grade NHL, when used upfront in patients with poor risk criteria 1, 2 and when included in salvage therapy in patients with chemosensitive relapses. 3 Several trials in progress suggest that it may also prolong disease-free survival (DFS) in patients with indolent NHL. [4] [5] [6] [7] [8] Over the past 15 years, data have accumulated in favor of purging the autograft from residual occult tumor cells. Effective graft purging, as evaluated by molecular biology detection of the bcl2-JH translocation 9, 10 or by tumor growth in vitro cultures, has been correlated to better outcome. 11 However, in the absence of randomized trials, the field remains controversial and there is no standard. In our team, in the past 15 years, blood and/or marrow tumor infiltration at intensification, as detected by cytology, histology or even more recently molecular biology, has remained a permanent contraindication for autografting.
We report on 33 NHL patients treated in our department, who were initially scheduled to undergo HDCT followed by ASCT, but because of persisting blood or marrow tumor cell involvement at the time of scheduled stem-cell collection, received instead, the BEAM pretransplant regimen followed by the administration of three growth factors, combining granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) without stem-cell reinfusion.
The data show that (1) the BEAM, although highly myelotoxic, is not myeloablative and the procedure is feasible (2) this strategy for poor risk patients who cannot be consolidated with ASCT has induced a high rate of remission.
Our patients were treated before the introduction of anti-CD20 monoclonal antibody (Rituximab) treatment in clinics. Rituximab has seriously modified the landscape with its use of pre-and post-transplant and the demonstration of its efficacy in terms of in vivo purging. Nonetheless, there are still situations today where the BEAM þ 3CK may be useful.
Patients and methods
From February 1994 to November 1999, 33 adult patients with NHL were treated according to the BEAM regimen, followed by growth-factor support without ASCT.
Patient characteristics at diagnosis
Patient characteristics are presented in Tables 1 and 2 . Systematic evaluation of BM and blood involvement was carried out by PCR for the bcl2-JH rearrangement and for rearrangement of the heavy chain of immunoglobulin (IgH). Accordingly, 27 patients had one or two tumor markers in BM and/or peripheral blood. Most patients have been heavily treated before intensification chemotherapy (Table 3) .
Intensification
The median age at intensification was 49 years (range, 31-66) years, with a median of 12 months (range, 4-52 months) from diagnosis to intensification. At the time of intensification, 29 of the 33 patients still had positive detection of tumor in marrow, by molecular biology (bcl2-JH and/or immunoglobulin heavy-chain rearrangement). All except for two patients had a platelet count 4100 000/mm.
All patients had backup hematopoietic stem-cell grafts, 26 peripheral blood and seven BM. Of the 27 patients who had a positive tumor marker at initial diagnosis (bcl2-JH or IgH), 24 had tumor backup graft contamination by PCR studies. Importantly, 10 backup grafts underwent positive CD34 þ selection (Ceprate SC, CellPro, Europe NVSA), but all remained with a positive tumor marker. Three patients with a positive tumor marker at diagnosis had no detectable graft contamination, but one of them still had dubious cytological BM tumor involvement before stem-cell harvest and another had chronic hepatitis B infection, which at the time of intensification, was considered to be a contraindication for ASCT.
Six patients had no tumor marker at diagnosis, of those, four had cytological BM involvement before stem-cell harvest. The two other patients had no BM involvement at diagnosis but one of them had a very poor backup graft.
Patient conditioning included the BEAM regimen: Carmustine (BCNU) 300 mg/m 2 on day -6, etoposide and cytarabine 200 mg/m 2 /day from days -5 to -2 and melphalan 140 mg/m 2 on day -1. Autologous stem-cell grafts were not injected. Starting from day 0, patients were treated systematically by three growth factors: intravenous (i.v.) G-CSF 5 mg/kg/day (filgrastime, Neupogen, Amgen) over 30 min, i.v. GM-CSF 5 mgkg/day (molgramostime, Leucomax, Schering-Plough, Novartis) over 6-8 h and i.v. EPO (Neorecormon, Roche) 150 U/kg/day on a 24 h continuous infusion (BEAM þ 3CK protocol). Growth factors were stopped gradually after stable hematopoietic recovery.
At 3 months postintensification, radiotherapy was delivered to 23 patients, as part of our institution's study on the impact of radiotherapy postintensification. 4 
Statistical analysis
Statistical analyses were independently performed for each end point, that is, relapse incidence (RI), toxic death, DFS and overall survival (OS). The incidence of each event was nonparametrically estimated. 12 Patients were censored at the time of relapse or at the last follow-up. Probability of OS and DFS were estimated by the product-limit method. The significance of differences between curves was estimated by the log-rank test (Mantel-Cox). Relapse and toxic death are events that compete with themselves. Accordingly, the estimation of the incidence of these two events were based on the nonparametric estimator of cumulative incidence curves, while predictive analyses were based on the proportional-hazards model for the subdistribution of competing risks. 13 Analyses were performed using the cmprsk package (developed by Gray, June 2001) on Splus 2000 software and SPSS software.
Results

Hematopoietic reconstitution
Out of 33 (91%), 30 patients recovered hematopoiesis. A total of 32 patients recovered their neutrophils (4500/mm 3 ) at a median of 19 days (range, 13-63 days). In total, 30 patients recovered their platelets (420 000/mm 3 ) at a median of 26 days (range, 12-250 days). One patient died on day 22 before neutrophil and platelet recovery. One patient died on day 78 after neutrophil recovery but before platelet recovery. A third patient had secondary BM failure after hematologic recovery and her backup graft was injected on day 90.
Factors associated with rapid hematopoietic reconstitution
Only age, richness of backup graft, blood hemoglobin level and platelet count before intensification were found to have an impact on hematological recovery (Table 4) .
Red blood cell (RBC) and platelet transfusion
The median requirement of RBC transfusions was 7 U of packed RBCs (range, 0-30). The median time to RBC transfusion independence was 19 days (range, 0-150 days). The median platelet transfusion requirement was 10 transfusions (range, 4-60). The median time to platelet transfusion independence was 26 days (range, 11-250 days).
Infectious complications
Patients had a median of two febrile days (temperature4381C) (range, 0-27 days) during hospitalization. A total of 12 patients developed infection and three of them died (Table 5) . Of the four patients who had cytomegalovirus (CMV) infection, one unfortunately died on day 87 from a bleeding complication after liver biopsy.
Outcome
The median follow-up was 62 months (range, 12-113 months). Five patients died from procedure-related mortality and eight from disease progression. A total of 20 patients are alive, 16 of them in CR. Patients' outcome according to histologic classification is presented in Table 6 . The 5-year DFS was 5279% (Figure 1 ), the RI was 35716%, mortality due to procedure 12712% and OS 61710% (Figure 2 ). Patients presently free of disease, all have normal blood counts except one who still has a platelet count o100 000/mm 3 , 52 months postintensification. None so far has developed a secondary malignancy such as myelodysplastic syndrome or acute leukemia. 
Discussion
High-dose chemotherapy using the BEAM protocol followed by ASCT is a well-established procedure. [1] [2] [3] [4] [5] [6] [7] [8] However, there is no published data concerning the capacity of BM to regenerate after BEAM chemotherapy in the absence of ASCT, inasmuch as the BEAM regimen was initially designed as a myeloablative regimen; consequently, there is no trial testing spontaneous recovery without ASCT support.
We published in 1989 our first case of a patient with NHL, who had failed conventional chemotherapies and had persisting massive BM infiltration, to whom we administered the BEAM followed by GM-CSF without ASCT.
14 Subsequently, in 1991, we reported on our first five NHL patients with BM involvement who were treated similarly. 15 Consequently, we then used a combination of growth factors available at that moment for clinical use, namely, G-CSF, GM-CSF and EPO. In vitro studies in our laboratory 16 showed that the combination of G-CSF, GM-CSF and EPO acts synergistically or additionally on the expansion of committed progenitors and was superior to the association of each of these cytokines used alone or in pairs. In ovarian and breast cancer patients, Pierelli et al 17 and Filip et al, 18 respectively, reported on significantly faster leukocyte and platelet recoveries and reduced the number of transfusions with the use of the combination of EPO and G-CSF after high-dose intensification and PBSC transplantation. In another study, Locatelli et al reported that EPO administered alone or in combination with G-CSF accelerated erythroid recovery and reduced red cell and platelet transfusion requirements in children undergoing allogeneic BMT. 19, 20 Taken altogether, these data supported the use of a combination of G-CSF, GM-CSF and EPO, after the BEAM, to enhance hematopoietic recovery. Our first patient treated in this way had an uneventful course post-BEAM and quickly recovered from aplasia. 21 In this study, we report on a series of 33 NHL patients, most of them with indolent lymphoma (22 out of 33) , who underwent the BEAM þ 3C protocol without ASCT from January 1994-2000. All patients had stem-cell collection before intensification, intended to serve as a backup. Many of these patients were heavily treated before the BEAM intensification due to resistant disease and were therefore considered as poor risk patients. The series we report here is historical. It concerns a period when anti-CD20 antibodies for treatment of NHL including in vivo purging prior to HSC mobilization and collection were not available. 22 At present, some of our patients may have achieved successful HSC harvesting leading to high-dose intensification and autografting with such additional therapy. Others probably, classified as refractory during this time period would not have likewise resisted to rituximab and, even till date, would not have been considered for ASCT. By using the G-CSF, GM-CSF and EPO combination, we were able to implement high-dose consolidation therapy and obtain fair hematopoietic reconstitution. Of interest were the findings that the richness of the backup graft in CD34 þ cells/kg, blood hemoglobin level and platelet count before HDCT correlated to the kinetics of hematopoietic recovery, presumably reflecting the magnitude of the remaining stem-cell pool, which could ultimately be stimulated in vivo by the three growth factors.
A procedure-related mortality of 12% may be considered acceptable in these heavily pretreated poor risk patients. The infectious complication rate is not different from what is usually observed following autografting. Concern has emerged in the late 1990s with regard to a possible increase in the overall infection rate and more specifically CMV infection, in patients autografted with CD34 þ purified grafts, due to lymphocyte depletion inducing poor lymphocyte recovery. 23, 26 It is of interest that in our series of patients, where no lymphocytes at all were reinfused, four CMV infections developed. Only one of them indirectly led to death through an unfortunate massive hemorrhage complicating a liver biopsy. CMV pre-emptive therapy should cover properly this issue.
Another concern was that we might find increased relapse rates following the BEAM þ 3CK due to prolonged immunosuppression. Taking into consideration the patients' grim prognosis, our results are acceptable, since even patients with poor risk disease obtained prolonged remission.
The role of graft purging in NHL remains controversial. Both the Dana Farber team using tumor detection by PCR for the bcl2-JH translocation 9, 10 and the Omaha team using tumor cell growth in cultures 11 have correlated the outcome of NHL patients post-ASCT to the quality of purging. In the absence of randomized trials, the definitive demonstration that in vitro purging indeed improves outcome is still missing. In this context, our experience is of potential interest, since no graft and therefore no tumor cell have been reinfused following the BEAM chemotherapy. Interestingly, two recent case reports have somewhat extended our BEAM þ 3CK experience to a certain extent. In the first one from our institution, a patient autografted twice for Hodgkin's disease had much better kinetics of engraftment following the second transplant with the three cytokines administered than after the first transplant with no cytokine being given. 24 In a second observation, Blaise et al 25 reported on an unexpectedly rapid rise in platelet counts with complete hematological recovery after a BEAM regimen in a patient who could not be rescued by an autologous transplant but who received filgrastim, epoietin alfa and stem-cell factor.
In conclusion, this series of patients shows that the BEAM þ 3CK regimen has been a therapeutic option for NHL patients who failed to respond to chemotherapy, in whom marrow or blood tumor contamination precluded autografting in our institution. We would consider today the same therapeutic option in patients resisting chemotherapy and rituximab. It is clear from this study that the BEAM widely used as a pretransplant regimen to consolidate mostly patients with NHL is not myeloablative and spares a residual hematopoietic stemcell pool, which can be expanded in vivo by cytokines to grow and differentiate. It can be administered even in patients with persistent tumor marrow or blood involvement and obtains an acceptable rate of long-term remissions. The BEAM þ 3CK has been our last therapeutic option in some patients with persisting hemopoietic involvement. In this population of patients still with a 50% risk of relapse, additional therapeutic measures can now be considered, such as anti-CD20 monoclonal antibodies or even a nonmyeloablative allogeneic transplant.
